Amryt Pharma PLC

Receive alerts
Market Cap:
£67.51 m
52 weeks high
52 weeks low

Viewing results 1-25 of 232


Euronext Growth Dublin Notice

1 day, 2 hours ago

Circular to Shareholders

1 week, 1 day ago

Amryt soars as US bankruptcy court clears way for Aegerion acquisition

Orphan drug firm Amryt said it would acquire Aegerion once the approved plan of reorganisation came into effect on or around 24 September...

1 week, 2 days ago

Schedule One - Amryt Pharma plc

2 weeks, 2 days ago

Schedule One

2 weeks, 2 days ago

Amryt Pharma provides detail of Aegerion deal

The group outlined the mechanics of the transformational transaction ...

3 weeks, 4 days ago

Open Orphan starts trading on AIM

Open Orphan was co-founded back in 2017 by Cathal Friel, the serial Irish investor behind companies such as Amryt Pharma and Fastnet...

on 28/6/19

Venn Life Sciences launches £4.5mln share placing to fund life after reverse takeover

The cash will be used to bankroll and grow the enlarged group...

on 11/6/19

Amryt Phama to take control of Lojuxta through merger with US firm Aegerion

Aegerion is a subsidiary of Nasdaq-listed Novelion Therapeutics and the way the deal has been structured values Amryt at US$120mln ...

on 21/5/19

Open Orphan set to join AIM as it agrees reverse takeover of Venn Life Sciences

Open Orphan was co-founded back in 2017 by Cathal Friel, the serial Irish investor behind companies such as Amryt Pharma and Fastnet...

on 10/5/19

Amryt Pharma creating the building blocks for commercial success

Driving growth was Lojuxta, used to treat a rare and life-threatening disorder that causes abnormally high levels of bad cholesterol. Its sales grew to €13.6mln, up 14.2% year-on-year...

on 17/4/19

Amryt Pharma given permission to extend age eligibility for drug trial

Amryt is developing AP101 as a potential treatment for Epidermolysis Bullosa, where skin blisters to the touch...

on 1/3/19

Amryt Pharma adds new element to promising portfolio

“If successful, this platform [AP103] has potential in other genetic skin conditions and beyond” ...

on 8/2/19

Amryt Pharma says new cream delivers encouraging early results

AP103 is a putative treatment for recessive dystrophic epidermolysis bullosa, a severe and very difficult to treat skin condition...

on 8/1/19

Amryt to add another 48 patients to Phase III trial of skin disorder cream

“The IDMC's recommendation is good news for Amryt as it allows us to continue the trial with only a modest increase in the size of the study”...

on 5/1/19

Amryt Pharma opens the first US site for its global AP101 EASE Phase III clinical trial for rare skin condition

The AIM-listed company also said it has received notification that the Independent Data Monitoring Committee is scheduled to meet on 21 December to review the EASE data...

on 19/12/18

Amryt Pharma receives €8.4mln from Irish government to develop treatment for rare skin condition

The grants will be paid out over the next three years and will fund the development of Amryt’s AP103 gene therapy platform, which has shown potential as a treatment for Recessive Dystrophic Epidermolysis Bullosa...

on 10/12/18

Amryt Pharma’s Lojuxta ‘bad’ cholesterol treatment to be made available in France in early 2019

The approval from French regulators means Lojuxta will soon be available in all five of the EU’s largest markets...

on 17/10/18